Fitusiran is being developed for haemophilia A and B in partnership with RNA interference (RNAi) specialist Alnylam – but has already been affected by safety issues.

The drug fitusiran, which will go by the brand name Qfitlia, is the first new treatment for both types of hemophilia — A and B. It can also be given to both patients who have antibodies that ...

approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood ...